Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo

(2010) Daniel Cejka et al.   CANCER BIOLOGY & THERAPY

POT1 deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells

(2010) Xiaoyan Ning et al.   EUROPEAN JOURNAL OF CANCER PREVENTION

Relation between outcomes and localisation of p-mTOR expression in gastric cancer

(2009) T Murayama et al.   BRITISH JOURNAL OF CANCER

Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

(2009) G. Yu et al.   CLINICAL CANCER RESEARCH

Positive Lymph Node Ratio Is an Independent Prognostic Factor in Gastric Cancer After D2 Resection Regardless of the Examined Number of Lymph Nodes

(2008) Da-zhi Xu et al.   ANNALS OF SURGICAL ONCOLOGY

Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues

(2008) Donghui Zhou et al.   BMC CANCER

Clinicopathologic significance of HIF-1α, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer

(2008) Sung Yong Oh et al.   BMC CANCER

An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer

(2008) T.S. Liu et al.   EJSO

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer

(2008) Mitsuru Sasako et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy

(2007) Leri S. Faried et al.   MOLECULAR CARCINOGENESIS